share_log

Even After Rising 3.6% This Past Week, DENTSPLY SIRONA (NASDAQ:XRAY) Shareholders Are Still Down 54% Over the Past Three Years

Even After Rising 3.6% This Past Week, DENTSPLY SIRONA (NASDAQ:XRAY) Shareholders Are Still Down 54% Over the Past Three Years

儘管上升了3.6%,登士柏(納斯達克:XRAY)股東在過去三年仍然下跌了54%。
Simply Wall St ·  09/16 07:32

If you love investing in stocks you're bound to buy some losers. But the long term shareholders of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) have had an unfortunate run in the last three years. Unfortunately, they have held through a 56% decline in the share price in that time. And the ride hasn't got any smoother in recent times over the last year, with the price 26% lower in that time.

如果你喜歡投資股票,你一定會買入一些輸家。但是,在過去的三年中,DENTSPLY SIRONA Inc.(納斯達克股票代碼:XRAY)的長期股東表現不佳。不幸的是,在那段時間內,他們的股價一直下跌了56%。而且在過去的一年裏,行程並沒有變得更加順利,同期價格下降了26%。

While the last three years has been tough for DENTSPLY SIRONA shareholders, this past week has shown signs of promise. So let's look at the longer term fundamentals and see if they've been the driver of the negative returns.

儘管過去三年對DENTSPLY SIRONA的股東來說是艱難的,但過去一週顯示出希望的跡象。因此,讓我們來看看長期基本面,看看它們是否是負回報的驅動力。

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

儘管一些人繼續教導高效市場假說,但事實證明,市場是反應過度的動態系統,投資者並不總是理性的。研究市場情緒如何隨着時間的推移而變化的一種方法是研究公司股價與其每股收益(EPS)之間的相互作用。

DENTSPLY SIRONA has made a profit in the past. However, it made a loss in the last twelve months, suggesting profit may be an unreliable metric at this stage. Other metrics may better explain the share price move.

DENTSPLY SIRONA 過去曾盈利。但是,它在過去十二個月中出現了虧損,這表明現階段的利潤可能是一個不可靠的指標。其他指標可以更好地解釋股價走勢。

With revenue flat over three years, it seems unlikely that the share price is reflecting the top line. We're not entirely sure why the share price is dropped, but it does seem likely investors have become less optimistic about the business.

由於三年來收入持平,股價似乎不太可能反映收入。我們不完全確定股價爲何下跌,但看來投資者對該業務的樂觀程度確實降低了。

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

下圖顯示了收入和收入隨時間推移的跟蹤情況(如果您點擊圖片,可以看到更多細節)。

big
NasdaqGS:XRAY Earnings and Revenue Growth September 16th 2024
納斯達克股票代碼:Xray 收益和收入增長 2024 年 9 月 16 日

It's probably worth noting we've seen significant insider buying in the last quarter, which we consider a positive. On the other hand, we think the revenue and earnings trends are much more meaningful measures of the business. So it makes a lot of sense to check out what analysts think DENTSPLY SIRONA will earn in the future (free profit forecasts).

可能值得注意的是,我們在上個季度看到了大量的內幕買盤,我們認爲這是積極的。另一方面,我們認爲收入和收益趨勢是衡量業務的更有意義的指標。因此,看看分析師認爲DENTSPLY SIRONA未來的收入(自由利潤預測)是很有意義的。

What About Dividends?

分紅呢?

When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. We note that for DENTSPLY SIRONA the TSR over the last 3 years was -54%, which is better than the share price return mentioned above. The dividends paid by the company have thusly boosted the total shareholder return.

在考慮投資回報時,重要的是要考慮股東總回報(TSR)和股價回報之間的差異。基於股息再投資的假設,股東總回報率納入了任何分拆或貼現資本籌集的價值以及任何股息。因此,對於支付豐厚股息的公司來說,股東總回報率通常遠高於股價回報率。我們注意到,對於DENTSPLY SIRONA而言,過去3年的股東總回報率爲-54%,好於上述股價回報率。因此,公司支付的股息提高了股東的總回報率。

A Different Perspective

不同的視角

While the broader market gained around 26% in the last year, DENTSPLY SIRONA shareholders lost 25% (even including dividends). Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 8% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with DENTSPLY SIRONA , and understanding them should be part of your investment process.

儘管去年整個市場上漲了約26%,但DENTSPLY SIRONA的股東卻損失了25%(甚至包括股息)。即使是優質股票的股價有時也會下跌,但我們希望在過於感興趣之前看到企業基本指標的改善。不幸的是,去年的表現可能預示着尚未解決的挑戰,因爲它比過去五年中8%的年化虧損還要糟糕。我們意識到羅斯柴爾德男爵曾說過,投資者應該 「在街頭流血時買入」,但我們警告說,投資者應首先確保他們購買的是高質量的企業。儘管市場狀況可能對股價產生的不同影響值得考慮,但還有其他因素更爲重要。例如,投資風險的幽靈無處不在。我們已經在DENTSPLY SIRONA中發現了一個警告信號,我們知道它們應該是您投資過程的一部分。

DENTSPLY SIRONA is not the only stock that insiders are buying. For those who like to find lesser know companies this free list of growing companies with recent insider purchasing, could be just the ticket.

DENTSPLY SIRONA並不是內部人士唯一買入的股票。對於那些喜歡尋找知名度較低的公司的人來說,這份最近有內幕收購的成長型公司的免費清單可能只是入場券。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文引用的市場回報反映了目前在美國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接聯繫我們。或者,也可以發送電子郵件至編輯團隊 (at) simplywallst.com。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論